The COMPASS Therapist Training Programme offers an evidence-based approach to psychotherapy training designed by leaders in psychology, psychiatry, and psychedelic therapy research. This programme equips mental health professionals with cutting-edge knowledge and practical skills for conducting COMP360 psilocybin therapy.
Designed for active, licensed mental health professionals, including clinical psychologists, clinical social workers, counsellors, and psychiatrists, the course fosters a deepened understanding of compassion, curiosity, openness, collaboration, presence, and cultural humility. The programme emphasizes developing a secure, genuine therapeutic relationship marked by trust, caring, confidentiality, and safety.
The curriculum is structured in a flexible, interactive format, including 10 hours of online theoretical learning, three days of in-person practical skills group training, and clinical training through recorded and live clinical sessions. By participating in this rigorous training, therapists will gain proficiency in leading sessions independently and achieve higher competency in their therapeutic skills.
Continuous professional development is supported through ongoing group mentoring, ensuring therapists stay at the forefront of therapeutic advancements. The programme is continuously revised and enhanced based on patient experiences and outcomes to ensure the highest quality of care.
Find More Info on COMPASS Therapist training programme on PsychedelicsCourses.com
COMPASS Pathways is a publicly listed company (NASDAQ) that is developing psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. COMPASS is one of the largest psychedelic companies and has received substantial investment from atai.